Company Overview and News


Add PFE
to your dashboard

Headline News

Are These The 6 Best Stocks In The Dow Jones Industrial Average? - Part 3 Of 5

15h valuewalk
In Part 1 and Part 2  of this series I covered 12 of the 30 Dow Jones Industrial Average stocks that I considered the most expensive of the index.  With this part 3 I will be looking at 6 additional Dow stocks that for the most part I would consider fully valued to only moderately overvalued.  What this suggests is that although I am not inclined to add new money at this point, I would not be anxious or worried about selling them at these levels either. (93-0)

Glaxo (GSK) Q3 Earnings: Will it Deliver a Beat Yet Again?

16h zacks
We expect GlaxoSmithKline plc (GSK - Free Report) to beat expectations when it reports third-quarter 2017 results on Oct 25, before the market opens. Last quarter, the company delivered a positive earnings surprise of 2.94%. (139-0)

Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2017 Update

2017-10-20 seekingalpha
Alibaba Group Holdings, Amazon.com, Visa Inc., Apple Inc., and Johnson & Johnson are the largest five individual stock positions. (1097-1)

Healthcare ETFs Head to Head: XLV vs. VHT

2017-10-19 zacks
The healthcare sector has been in the spotlight lately. President Donald Trump targeted drug companies and accused them of charging extremely high prices (read: ETFs in Focus as IMF ups Global Growth Forecast). (11-0)

Healthcare ETFs in Focus on Johnson & Johnson Q3 Earnings

2017-10-19 zacks
Shares of Johnson & Johnson (JNJ - Free Report) increased 3.5% at market close on Oct 17, 2017 after beating the Zacks Consensus Estimate on both earnings and revenues. The company’s revenues of $19.7 billion increased 10.3% in third-quarter 2017 on a year-over-year basis and 4.5% on a sequential basis. It came ahead of the consensus mark of $19.28 billion. (11-0)

Conatus Entrusts Keith W. Marshall With Key Management Roles

2017-10-19 zacks
Conatus Pharmaceuticals Inc. (CNAT - Free Report) announced the appointment of Keith W. Marshall as executive vice president, chief operating officer and chief financial officer. (247-2)

Why Are These 6 Dow Stocks Fairly Valued?: Part 4 Of 5

2017-10-19 seekingalpha
The Dow Jones Industrial Average is at an all-time high, but here are six that are fairly valued. (199-0)

A KISS Dividend Strategy Worth 15% A Year

2017-10-19 seekingalpha
Quantitative investing aims at making systematic investment decisions based on hard data. Quantitative models make the investment process: (42-0)

What to Expect from Big Pharmas After J&J's Solid Q3 Results?

2017-10-18 zacks
Johnson & Johnson (JNJ - Free Report) was the first large-cap pharma stock to report its earnings results for this season on Oct 17. J&J beat the Zacks Consensus Estimate for both earnings and revenues in the third quarter and also raised its 2017 sales and profit outlook. Shares of J&J were up more than 3% on Tuesday. (23-0)

BRIEF-Pfizer reports 5.4 pct passive stake in Rhythm Pharmaceuticals - ‍​SEC filing

2017-10-18 reuters
* Pfizer Inc reports 5.4 percent passive stake in Rhythm Pharmaceuticals Inc as of October 10, 2017 - ‍​SEC filing Source text: (bit.ly/2ywc5E7) Further company coverage: (Bengaluru Newsroom: +91 806 749 1136) (16-0)

Dow Jones Industrial Average Hits 23,000. Now What? | InvestorPlace

2017-10-18 investorplace
On Oct. 18, the Dow Jones Industrial Average hit a new all-time intraday high of 23,145 as of this writing. Investors who aren’t playing the indices can gain exposure to the Dow Jones today through the SPDR Dow Jones Industrial Average ETF (NYSEARCA:DIA). With the index up 16.3% in 2017, though, how much longer can this rally continue? (364-0)

Only 16 Of 61 Are 'Safer' Dividend Healthcare Dogs For October

2017-10-18 seekingalpha
Top "safer" dividend Healthcare dog, GSK's 16.2% net gain was 58% more than MRK's 10.4% second place effort, and 100% over PFE's fourth place result per analyst targets 10/13/17. (91-0)

Biogen (BIIB) Q3 Earnings: Will it Deliver a Beat Again?

2017-10-18 zacks
We expect Biogen Inc. (BIIB - Free Report) , a well-known name in the multiple sclerosis (MS) market, to beat expectations when it reports third-quarter 2017 results on Oct 24, before the market opens. Last quarter, the company delivered a positive earnings surprise of 15.60%. (130-0)

Healthcare Dogfight: Owens & Minor Edges GlaxoSmithKline As Top Broker Pick For Gains In October

2017-10-18 seekingalpha
The Healthcare sector is composed of ten component industries. The top 50 firms selected by yield for this writing represented all of those industries. (174-0)

Pfizer's Advil May Be Just the Thing for Sickly Reckitt - Bloomberg

2017-10-18 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (16-0)

iShares U.S. Healthcare ETF (IYH) Hits New 52-Week High

2017-10-18 zacks
For investors seeking momentum, iShares U.S. Healthcare ETF (IYH - Free Report) is probably on radar now. The fund just hit a 52-week high and is up nearly 27.7% from its 52-week low price of $137.30/share. (23-0)

Eli Lilly (LLY) to Report Q3 Earnings: What's in Store?

2017-10-18 zacks
Eli Lilly and Company (LLY - Free Report) will report third-quarter 2017 results on Oct 24, before the market opens. Last quarter, the company delivered a positive earnings surprise of 6.73%. (89-0)

Reckitt CEO Focuses on Health, Looking Beyond Worst Year - Bloomberg

2017-10-18 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (69-0)

Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks

2017-10-18 zacks
Although pharma and biotech stocks had gone through a rough patch due to the drug pricing controversy, the sector is showing signs of recovery, with investors being more comfortable with the drug pricing scenario and focusing on the fundamentals of the sector instead. Innovation, mergers and acquisitions (M&As), strong results, product approvals and positive data flow should act as catalysts for pharma and biotech stocks. (87-0)

Aerie (AERI) Up on FDA Review Committee Result for Rhopressa

2017-10-18 zacks
Shares of Aerie Pharmaceuticals, Inc. (AERI - Free Report) have moved up 15.8% in the last one week on positive news for its lead drug, Rhopressa. (106-0)

Your Daily Pharma Scoop: Everybody's Gilead Problem, Halozyme's Further Progress, Ziopharm's Gene Therapy

2017-10-17 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (305-2)

J&J (JNJ) Beats on Q3 Earnings, Actelion Buyout Drives Sales

2017-10-17 zacks
Johnson & Johnson (JNJ - Free Report) reported better-than-expected third-quarter 2017 results, beating the Zacks Consensus Estimate for both earnings and sales. The drug and consumer products giant raised its 2017 sales and profit outlook, which sent shares up 1.5% in pre-market trading. (81-0)

Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen

2017-10-17 zacks
Chicago, IL – October 17, 2017 – Today, Zacks Equity Research discusses the Industry: Pharmaceuticals, Part 1, including Gilead (Nasdaq:(GILD - Free Report)  – Free Report), Teva (NYSE:(TEVA - Free Report)  – Free Report), Pfizer (NYSE:(PFE - Free Report)  – Free Report) and Amgen (Nasdaq:(AMGN - Free Report)  – Free Report). (131-0)

Corbus Pharmaceuticals Appoints Paris Panayiotopoulos to Its Board of Directors

2017-10-17 marketwired
NORWOOD, MA--(Marketwired - October 17, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it has appointed Mr. Paris Panayiotopoulos to its Board of Directors. (152-0)

Avoid This Credit Card And Travel Services Company With Poor Total Return

2017-10-17 seekingalpha
American Express has increased its dividend for 6 of the past ten years and has a present yearly yield of 1.5%. (154-0)

CUSIP: 717081103